PHAR Relative Valuation
PHAR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PHAR is overvalued; if below, it's undervalued.
Historical Valuation
Pharming Group NV (PHAR) is now in the Fair zone, suggesting that its current forward PS ratio of 2.92 is considered Fairly compared with the five-year average of -59.73. The fair price of Pharming Group NV (PHAR) is between 11.38 to 17.21 according to relative valuation methord.
Relative Value
Fair Zone
11.38-17.21
Current Price：16.28
Fair
223.87
PE
1Y
3Y
5Y
Trailing
Forward
48.45
EV/EBITDA
Pharming Group NV. (PHAR) has a current EV/EBITDA of 48.45. The 5-year average EV/EBITDA is 142.25. The thresholds are as follows: Strongly Undervalued below -376.47, Undervalued between -376.47 and -117.11, Fairly Valued between 401.61 and -117.11, Overvalued between 401.61 and 660.97, and Strongly Overvalued above 660.97. The current Forward EV/EBITDA of 48.45 falls within the Historic Trend Line -Fairly Valued range.
22.50
EV/EBIT
Pharming Group NV. (PHAR) has a current EV/EBIT of 22.50. The 5-year average EV/EBIT is 339.69. The thresholds are as follows: Strongly Undervalued below -2548.20, Undervalued between -2548.20 and -1104.25, Fairly Valued between 1783.63 and -1104.25, Overvalued between 1783.63 and 3227.58, and Strongly Overvalued above 3227.58. The current Forward EV/EBIT of 22.50 falls within the Historic Trend Line -Fairly Valued range.
2.91
PS
Pharming Group NV. (PHAR) has a current PS of 2.91. The 5-year average PS is 2.78. The thresholds are as follows: Strongly Undervalued below 1.48, Undervalued between 1.48 and 2.13, Fairly Valued between 3.44 and 2.13, Overvalued between 3.44 and 4.09, and Strongly Overvalued above 4.09. The current Forward PS of 2.91 falls within the Historic Trend Line -Fairly Valued range.
172.83
P/OCF
Pharming Group NV. (PHAR) has a current P/OCF of 172.83. The 5-year average P/OCF is 24.00. The thresholds are as follows: Strongly Undervalued below -641.83, Undervalued between -641.83 and -308.91, Fairly Valued between 356.92 and -308.91, Overvalued between 356.92 and 689.83, and Strongly Overvalued above 689.83. The current Forward P/OCF of 172.83 falls within the Historic Trend Line -Fairly Valued range.
-295.26
P/FCF
Pharming Group NV. (PHAR) has a current P/FCF of -295.26. The 5-year average P/FCF is 1.27. The thresholds are as follows: Strongly Undervalued below -293.76, Undervalued between -293.76 and -146.25, Fairly Valued between 148.79 and -146.25, Overvalued between 148.79 and 296.30, and Strongly Overvalued above 296.30. The current Forward P/FCF of -295.26 falls within the Strongly Undervalued range.
Pharming Group NV (PHAR) has a current Price-to-Book (P/B) ratio of 30.01. Compared to its 3-year average P/B ratio of 11.78 , the current P/B ratio is approximately 154.69% higher. Relative to its 5-year average P/B ratio of 8.47, the current P/B ratio is about 254.26% higher. Pharming Group NV (PHAR) has a Forward Free Cash Flow (FCF) yield of approximately 4.81%. Compared to its 3-year average FCF yield of 0.10%, the current FCF yield is approximately 4731.38% lower. Relative to its 5-year average FCF yield of 2.41% , the current FCF yield is about 99.10% lower.
32.93
P/B
Median3y
11.78
Median5y
8.47
4.83
FCF Yield
Median3y
0.10
Median5y
2.41
Competitors Valuation Multiple
The average P/S ratio for PHAR's competitors is 1.45, providing a benchmark for relative valuation. Pharming Group NV Corp (PHAR) exhibits a P/S ratio of 2.91, which is 100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PHAR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PHAR in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Pharming Group NV (PHAR) currently overvalued or undervalued?
What is Pharming Group NV (PHAR) fair value?
How does PHAR's valuation metrics compare to the industry average?
What is the current P/B ratio for Pharming Group NV (PHAR) as of Dec 05 2025?
What is the current FCF Yield for Pharming Group NV (PHAR) as of Dec 05 2025?
What is the current Forward P/E ratio for Pharming Group NV (PHAR) as of Dec 05 2025?